Abstract
China remains one of the countries with a high burden of tuberculosis (TB), with an estimated 748, 000 cases each year, ranking third in the world. The research and development of new drugs and new protocols plays a key role in the face of the requirements of the WHO's End TB Strategy. There are multiple new drugs in the clinical trial stage, such as macozinone, sutezoid, alpiberctin, and GSK3036656. The effectiveness, safety, and resistance issues of marketed drugs such as linezolid, bedaquiline, and delamanid are also of great concern. Meanwhile, short-term treatments for sensitive and drug-resistant TB have always been a hot topic in clinical research. WHO has also updated the preventive treatment plan for people at high risk of TB. This article reviews the literature published from October 1, 2023 to September 30, 2024.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call